Recurrence Patterns and Efficacy of Surveillance Modalities for Sinonasal Malignancies.
Am J Rhinol Allergy
; 36(4): 473-479, 2022 Jul.
Article
en En
| MEDLINE
| ID: mdl-35238217
ABSTRACT
OBJECTIVE:
There is limited information regarding the recurrence patterns and efficacy of surveillance modalities in patients with sinonasal malignancies.METHODS:
A retrospective study was conducted between the years 2001-2018 at a tertiary care center. Included were all patients with sinonasal malignancies treated in our institution. Data regarding recurrence and survival were analyzed.RESULTS:
Eighty-one patients were included. Multimodal treatment was administered to the majority of patients. 24 (35.3%) patients recurred with a median time of 17 months (range, 4-180). Although the majority of recurrences occurred within the first 5 years (83.3%), 4 (16.6%) recurred later on (5-15 years). Recurrences were local in 83.3%, regional in 20.8% and distant in 16.6%. All local recurrences occurred within the radiation treatment field and all patients with distant failure had mucosal melanoma. The majority of recurrences (70.6%) were diagnosed clinically or endoscopically, mainly in patients with SCC during the first 2 years of follow up. MRI or PET-CT were crucial in detecting extra-sinus and distant failures. Salvage surgery was feasible in the majority of patients (58.3%). Overall, 5 years survival (OS) rate was 60.9%.CONCLUSIONS:
Frequent clinic visits with nasal endoscopy combined with frequent imaging studies should be routinely practiced as part of a long-term surveillance plan. Longer follow up duration should be considered in these patients.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias de los Senos Paranasales
/
Neoplasias Nasales
Tipo de estudio:
Observational_studies
/
Screening_studies
Límite:
Humans
Idioma:
En
Revista:
Am J Rhinol Allergy
Asunto de la revista:
ALERGIA E IMUNOLOGIA
/
OTORRINOLARINGOLOGIA
Año:
2022
Tipo del documento:
Article
País de afiliación:
Israel